Education
About Us
Working with TipRanks
Follow Us
Hansa Biopharma AB (SE:HNSA)
:HNSA
HNSA Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr19.58 - kr57.30
Previous CloseN/A
Volume97.73K
Average Volume (3M)142.45K
Market Cap
kr1.46B
Enterprise Valuekr3.33B
Total Cash (Recent Filing)kr339.93M
Total Debt (Recent Filing)kr15.23M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Apr 17, 2025EPS Estimate
-2.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.08
Shares Outstanding67,814,240
10 Day Avg. Volume122,573
30 Day Avg. Volume142,454
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr143.00Price Target Upside535.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Hansa Biopharma AB News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe completion of patient enrollment in the pivotal Phase 3 trial for anti-GBM disease is ahead of schedule, highlighting the company's progress and the unmet needs in the autoimmune space.
Market AccessThe company now has reimbursement in key regions in Spain, a strong transplant market.
Product DevelopmentImlifidase combined with IVIg accelerated muscle strength recovery in GBS patients, demonstrating its therapeutic potential in acute autoimmune conditions beyond kidney transplantation.
Bears Say
Financial RisksRisks include financial, because the company has capital needs that exceed current cash balance.
Reimbursement ChallengesReimbursement risk, because the high cost of imlifidase may cause payors to resist coverage.
Sales PerformanceIdefirix's 4Q sales disappointed with product sales of SEK25.6M, representing a 41% YoY and a 36% QoQ decrease, which was below estimate.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
― Other Institutional Investors
99.74% Public Companies and
Individual Investors
HNSA FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest stock price was kr19.58 and its highest was kr57.30 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is kr1.46B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Apr 17, 2025 which is 8 days ago.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Feb 06, 2025. The company reported -kr4.08 earnings per share for the quarter, missing the consensus estimate of -kr1.981 by -kr2.099.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is -2.65.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 67,814,240 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -kr4.08 in its last earnings report, missing expectations of -kr1.981. Following the earnings report the stock price went down -19.393%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in SE:HNSA
---
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (HNSA) is a leading biopharmaceutical company based in Sweden, focused on developing innovative immunomodulatory treatments for rare immunologic diseases. The company operates within the healthcare and biotechnology sectors, specializing in enzyme technology to address unmet medical needs. Its core product, Idefirix® (imlifidase), is designed to inactivate IgG antibodies, facilitating life-saving organ transplants in highly sensitized patients.
---
HNSA Stock 12 Month Forecast
Average Price Target
kr143.00
▲(535.56% Upside)
Technical Analysis
BioInvent International AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
SynAct Pharma AB
―
Best Analysts Covering HNSA
1 Year
1 Year Success Rate
2/21 ratings generated profit
1 Year Average Return
-24.37%
reiterated a buy rating 2 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 9.52% of your transactions generating a profit, with an average return of -24.37% per trade.
---